Tag Archives: Zymeworks Inc.

December, 2015

  • 3 December

    GSK Partners with Zymeworks in $440 Million Antibody Collaboration

    Vancouver, Canada – Zymeworks Inc. today announced that it has entered into a collaboration and license agreement with GlaxoSmithKline (GSK) for the research, development, and commercialization of novel Fc-engineered monoclonal and bi-specific antibody therapeutics which have been optimized for specific therapeutic effects. Under the terms of the agreement, Zymeworks and …